LENZ Therapeutics, Inc. (LENZ)
Company Description
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.
The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene.
It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020.
Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
Country | Canada |
Founded | 2019 |
IPO Date | Jun 25, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 6 |
Contact Details
Address: 445 Marine View Ave Suite 320 Del Mar, California 92014 United States | |
Phone | 858-925-7000 |
Stock Details
Ticker Symbol | LENZ |
Exchange | NASDAQ |
Fiscal Year | January - December |
IPO Price | $17.00 |
CIK Code | 0001815776 |
ISIN Number | US38870X1046 |
Employer ID | 84-4867570 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Kimberlee Cobleigh Drapkin CPA | President, Chief Executive Officer, Chief Operating Officer, Principal Executive, Financial and Accounting Officer and Director |
Dr. Matthew Porteus M.D., Ph.D. | Academic Founder and Director |
Stephanie Yao | Vice President of Communications and Investor Relations |
Dr. Christine Garrett P.M.P., Ph.D. | Chief Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 22, 2024 | 8-K | Current Report |
Mar 19, 2024 | 8-K | Current Report |
Mar 14, 2024 | 8-K | Current Report |
Mar 8, 2024 | 425 | Filing |
Mar 8, 2024 | 8-K | Current Report |
Mar 5, 2024 | 425 | Filing |
Mar 5, 2024 | 8-K | Current Report |